In a phase 3 clinical trial, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP ...

Medical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis. The drug behind Ozempic and Wegovy ...

A study in mice and people with osteoarthritis suggests semaglutide can bulk up cartilage between bones, though bigger trials are needed to confirm.

Semaglutide is at least as effective at preventing heart attacks and other cardiac events as well as death in people with impaired kidney function as it is in those with normal kidney function The ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

CagriSema did not meet the noninferiority threshold for weight loss compared with tirzepatide in a phase 3 trial of patients with obesity.

The use of semaglutide, a medication from the class of GLP-1 receptor agonists, has become increasingly popular. The brands Rybelsus and Ozempic are currently FDA-approved for diabetes management, and ...

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had ...

Weight management medications are transforming the landscape of obesity treatment, with semaglutide emerging as a groundbreaking solution for individuals struggling with weight loss. As demand surges ...

Patients with type 2 diabetes and a baseline HbA1c greater than 7.0% experienced greater cardiovascular benefits while using oral semaglutide. Oral semaglutide elicits more pronounced cardiovascular ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current research ...